72 related articles for article (PubMed ID: 565049)
1. Biological properties of fibrinogen derivatives relevant to the function of cardiovascular system and immuno-inflammatory reaction.
Kopec M
New Istanbul Contrib Clin Sci; 1977 Sep; 12(1):43-9. PubMed ID: 565049
[No Abstract] [Full Text] [Related]
2. [Biological properties of fibrinogen degradation products by thrombin].
Buczko W
Pol Tyg Lek; 1981 Jun; 36(23):855-6. PubMed ID: 7024948
[No Abstract] [Full Text] [Related]
3. Fibrinogen and its derivatives: cofactors in the intrinsic generation of thrombin.
Triantaphyllopoulos DC; Ryan LT
Thromb Haemost; 1976 Apr; 35(2):305-13. PubMed ID: 989630
[TBL] [Abstract][Full Text] [Related]
4. Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis.
Smith EB
Clin Haematol; 1986 May; 15(2):355-70. PubMed ID: 3524931
[TBL] [Abstract][Full Text] [Related]
5. [Thrombus formation with special reference to the substrates, fibrinogen and its related substances].
Matsuda M
Rinsho Ketsueki; 1984 Jul; 25(7):984-91. PubMed ID: 6502959
[No Abstract] [Full Text] [Related]
6. [Biological effect of fibrin/fibrinogen degradation products].
Li SQ
Sheng Li Ke Xue Jin Zhan; 1986 Apr; 17(2):169-72. PubMed ID: 3538403
[No Abstract] [Full Text] [Related]
7. [Monoclonal antibodies against fibrinogen and fibrin and against their proteolytic degradation products].
Dyr JE; Cajthamlová H; Suttnar J
Cas Lek Cesk; 1990 Oct; 129(43):1349-51. PubMed ID: 2249231
[TBL] [Abstract][Full Text] [Related]
8. Proteolytic degradation products from fibrinogen and fibrin with special respect to non-covalently associated complexes. Influence of fibrin crosslinking. Lysability and other properties.
Feddersen C
Scand J Clin Lab Invest Suppl; 1983; 166():1-60. PubMed ID: 6226084
[No Abstract] [Full Text] [Related]
9. Fibrinogen-fibrin degradation products.
Kwaan HC
Ann Clin Lab Sci; 1980; 10(3):234-7. PubMed ID: 7396389
[TBL] [Abstract][Full Text] [Related]
10. Fibrinogen degradation products do not affect the hypertensive action of dopamine.
Buczko W; Wiśniewski K
Acta Med Pol; 1986; 27(1-2):31-6. PubMed ID: 3565076
[No Abstract] [Full Text] [Related]
11. [Fibrinogen and plantar edema induced by lambda carrageenan].
Damas J
C R Seances Soc Biol Fil; 1981; 175(2):269-73. PubMed ID: 6454475
[TBL] [Abstract][Full Text] [Related]
12. Biological effects of fibrinogen-fibrin degradation products.
Larrieu MJ; Dray L; Ardaillou N
Thromb Diath Haemorrh; 1975 Dec; 34(3):686-92. PubMed ID: 1108283
[No Abstract] [Full Text] [Related]
13. Anticoagulant properties of purified X-like fragments of human fibrinogen produced by degradation with leukocyte elastase.
Sterrenberg L; van Liempt GJ; Nieuwenhuizen W; Hermans J
Thromb Haemost; 1984 Jul; 51(3):398-402. PubMed ID: 6238443
[TBL] [Abstract][Full Text] [Related]
14. Catabolism of purified rat fibrin(ogen) plasmin degradation products in rats.
Nieuwenhuizen W; Emeis JJ; Vermond A
Thromb Haemost; 1982 Aug; 48(1):59-61. PubMed ID: 7135343
[TBL] [Abstract][Full Text] [Related]
15. [The current opinion on inflammatory, biochemistry and hemostatic markers and factors in atherosclerosis. Part II].
Rajtar R; Kloch M; Bober M; Kolasińska-Kloch W
Przegl Lek; 2006; 63(9):767-72. PubMed ID: 17479867
[TBL] [Abstract][Full Text] [Related]
16. Lymphocyte suppressive peptides from fibrinogen are derived predominantly from the A alpha chain.
Plow EF; Edgington TS
J Immunol; 1986 Sep; 137(6):1910-5. PubMed ID: 2943807
[TBL] [Abstract][Full Text] [Related]
17. The ability of fibrinogens, FI and FII, to support ADP-induced platelet aggregation.
Phillips HM; Mansouri A; Perry CA
Thromb Haemost; 1983 Aug; 50(2):527-9. PubMed ID: 6636032
[TBL] [Abstract][Full Text] [Related]
18. New structural and functional properties of fibrinogen and its early homologue, fragment X.
Rozenfel'd MA; Kostanova EA; Vasil'eva MV; Leonova VB
Dokl Biochem Biophys; 2001; 378():191-4. PubMed ID: 11712177
[No Abstract] [Full Text] [Related]
19. [Relevance of fibrinogen/fibrin degradation products in the study of thrombosis].
Páramo JA; Gaffney PJ
Sangre (Barc); 1989 Dec; 34(6):497-501. PubMed ID: 2697948
[No Abstract] [Full Text] [Related]
20. Lack of effects of fibrinogen degradation products on specific binding of [3H]spiroperidol and [3H]ADTN.
Buczko W; De Blasi A
Pol J Pharmacol Pharm; 1983; 35(1):45-7. PubMed ID: 6889186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
